Medical Developments International Limited · ASX:MVP
Medical Developments International — FY2022 Earnings Presentation
21 slides from Medical Developments International's earnings presentation, Aug 26, 2022
Slide 1: FY22 Full Year Results
ASX:MVP FY22 Full Year Results 26 August 2022
Slide 2: Important Information
IMPORTANT INFORMATION This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, a
Slide 3: Key messages: Well positioned for growth
Key messages Well positioned for growth 1. Strong revenue growth in FY22 in a COVID impaired Company overview • Medical Developments International Limited environment; Penthrox and Respiratory performing well (ASX:MVP) is an Australian based pain management and respiratory company 2. Direct sales st
Slide 4: Financial highlights
FY22 results Financial highlights Revenue Pain Management Revenue Respiratory Revenue $22.4m $13.7m $8.2m +37% (underlying) 1 +29% 1 (underlying) +53% Reported EBIT NPAT Cash at bank $(15.9)m $(12.4)m $20.4m 4 1. Prior year excludes Mundipharma contract termination income of $8.9m
Slide 5: Building a strong foundation
FY22 achievements Building a strong foundation • European regional platform established and in-market sales team deployed in France, growth in FY22 affirms direct sales strategy • Leadership team transformed - with strong international and industry experience providing a deeper focus on commercial e
Slide 6: Driving our transformation
Leadership and capability Driving our transformation Investment in leadership and capability will underpin execution of strategy • Transformation of the leadership team New appointments in finance, legal, human resources, medical affairs, clinical development and quality • Enhanced functional teams
Slide 7: Financial Performance
FINANCIAL PERFORMANCE
Slide 8: FY22 full year results
Financial summary FY22 full year results Commentary $million FY21 FY22 Change % • Strong growth in underlying revenue up 37% to Reported revenue 25.3 22.4 (11%) $22.4m Reported EBIT (14.9) (15.9) (6%) • Disruption to sales from COVID restrictions throughout most of the period, particularly in NPAT (
Slide 9: Strong growth in all markets
Revenue and volume Strong growth in all markets Underlying revenue ($million) FY21 FY22 Change % Commentary Product revenue 9.1 13.3 46% Milestone and other revenue 1.5 0.4 (73%) Pain management revenue up 29% Pain Management 10.6 13.7 29% driven by strong volume growth Respiratory 5.4 8.2 53% • Fra
Slide 10: Building a platform for future growth
EBIT bridge Building a platform for future growth Commentary Underlying EBIT bridge ($millions) • Higher Penthrox and Respiratory volumes Investment in Investment in European Leadership and • Higher margins driven by growth in direct FY21 Underlying Volume and Distribution regional functional Other
Slide 11: Underpinning our growth strategy
Capital raise Underpinning our growth strategy The capital raise in August 2022 has provided approximately $28.5 million to underpin the delivery of strategy Proposed use of funds Investment in direct sales resources that will support the growth $15.3m in Australia and Europe respectively, along wit
Slide 12: FY23 Priorities and Outlook
FY23 PRIORITIES AND OUTLOOK
Slide 13: Continue to grow Penthrox in France
European growth strategy Continue to grow Penthrox in France Leverage established in-market sales Targeting capability to deepen penetration in existing ~110,000 units in FY23 customers and broaden market reach ~110 • Direct sales capability established 9 key account managers fully deployed 60 • Sup
Slide 14: Prepare for expansion in nearby markets
European growth strategy Prepare for expansion in nearby markets A direct sales approach in key markets Current penetration in France is accelerating the commercialisation of highlights significant market Australia Penthrox, growing volumes and expanding potential relative to global 11,577 margins b
Slide 15: Drive penetration in Australian emergency departments
Australian business expansion Drive penetration in Australian emergency departments Invest in direct sales capability to broaden Attractive market market penetration opportunity1 Procedural ppointment of direct sales team • A 17% Expected in H1 FY23 Ambulance 31% Outpatients • Will drive penetration
Slide 16: Trial planning advancing
USA Phase III trials Trial planning advancing Unconditional go ahead for Penthrox US trial received from FDA “We have completed • Trial planning is advancing the review of your submissions and have • First patient enrolment in US trial now likely in calendar year 2023 concluded that the clinical tri
Slide 17: Strong revenue growth expected
FY23 outlook Strong revenue growth expected Driving the trajectory: • Significant growth in France • Penetration in Australian hospital emergency departments • Continued growth in Australian ambulance segment • Enhanced distributor engagement • Further market share gains in the Respiratory segment,
Slide 18: Appendix
lopments International
Slide 19: Penthrox: over 8 million used worldwide
Penthrox Over 8 million used worldwide The superior efficacy, safety and administration The iconic Green Whistle benefits of Penthrox deliver improved patient outcomes and lower overall costs • Inhaled needle-free analgesic1 • Non-opioid1 • Portable, self administered device1 • Effective pain relief
Slide 20: Assisting patients manage asthma and COPD
Respiratory Assisting patients manage asthma and COPD 1 Providing pharmacies, medical clinics and hospitals with a range of respiratory devices which are designed to assist At home On the go patients to manage asthma and COPD1 •Space chambers •Portable nebulisers •Silicon Face Masks 20 1. Chronic Ob
Slide 21: FY22 Full Year Results
ASX:MVP FY22 Full Year Results 26 August 2022
Medical Developments International — FY2022 Earnings Presentation on 6ix